Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
New movies to watch this weekend: See 'The Drama' in theaters, rent 'Wuthering Heights,' stream 'Pizza Movie' on Hulu- Scientists sent a menstrual cup to space. This is how it went
- Prehistoric wolf’s gut frozen in time reveals an ice age giant
- Former hostage Eitan Mor on Hamas: ‘They will not give up until the last Israeli is gone'
- Rescuers attempt to dig free whale stranded on Germany's Baltic coast
- When preventable infections turn deadly behind bars | The Excerpt
- Orbán orders stop to gas deliveries to Ukraine via Hungary from July
- Figure out How to Function Successfully with Your Auto Collision Legal advisor for the Best Result
- Kids with smartphones by age 12 are at higher risk of health issues, study finds
